

IN THE CLAIMS

1-26. (canceled)

27. (currently amended) An *in vitro* method of treating a neoplastic cell, comprising:
administering to the cell a therapeutically effective amount of antisense oligonucleotides which are complementary to: an mRNA comprising nucleotides 312-1784 of SEQ ID NO:2 and encoding ~~a coding sequence for~~ human MDM2₁, and which inhibit expression of human MDM2 protein.

28-55. (canceled)

56. (currently amended) An *in vitro* method of treating a cell having an amplified human MDM2 gene, elevated expression of human MDM2 mRNA, or elevated expression of human MDM2 protein, comprising:

administering to the cell a therapeutically effective amount of antisense oligonucleotides which are complementary to an mRNA comprising nucleotides 312-1784 of SEQ ID NO:2 and encoding ~~a coding sequence for~~ human MDM2 and which inhibit expression of human MDM2 protein.

57-61. (canceled)

62. (currently amended) An *in vitro* method of interfering with expression of human MDM2 protein, comprising administering to a neoplastic cell an antisense oligonucleotide which is complementary to: an mRNA comprising nucleotides 312-1784 of SEQ ID NO:2 and encoding ~~a coding sequence for~~ human MDM2₁, in an amount effective to interfere with expression of human MDM2 protein.

63. (currently amended) An *in vitro* method of interfering with expression of human MDM2 protein, comprising:

administering to a cell having an amplified human MDM2 gene, elevated expression of human MDM2 mRNA, or elevated expression of human MDM2 protein an antisense oligonucleotide which is complementary to: an mRNA comprising nucleotides 312-1784 of SEQ ID NO:2 and encoding ~~a coding sequence for~~ human MDM2, in an amount effective to interfere with expression of human MDM2.

64. (new) The method of claim 27 wherein the antisense oligonucleotides comprise at least 34 contiguous nucleotides.

65. (new) The method of claim 56 wherein the antisense oligonucleotides comprise at least 34 contiguous nucleotides.

66. (new) The method of claim 62 the antisense oligonucleotides comprise at least 34 contiguous nucleotides.

67. (new) An antisense oligonucleotide which comprises at least 34 contiguous nucleotides and which is complementary to: an mRNA comprising nucleotides 312-1784 of SEQ ID NO:2 and encoding human MDM2.